Along with CAR-T cell treatment, bispecific antibodies has been one of the most important topics discussed at the American Society (ASH) Annual Meeting. This family of drugs has shown very promising results in early phases of clinical trials in heavily pre-treated myeloma patients. Dr Mohamad Mohty, Head of Haematology and and Celular Therapy Department, …
By Finn Bo Petersen, Mohamad Mohty & 1 more. “the doctor kept looking into the computer screen on their desk during the whole consultation and…
We welcome you to join a special webinar for Practicing Hematologists on how to prevent burnout and cultivate satisfaction and fulfillment. In today’s practice of…
We welcome you to join a special webinar for Practicing Hematologists on how to prevent burnout and cultivate satisfaction and fulfillment. In today’s practice of…
By Mohamad Mohty, Kanti Rai. Dr Rai is the chief of Northwell Health’s CLL Research and Treatment Program. He is internationally recognized for his expertise…
We welcome you to join a special webinar for Practicing Hematologists on how to prevent burnout and cultivate satisfaction and fulfillment. In today’s practice of…
We welcome you to join a special webinar for Practicing Hematologists on how to prevent burnout and cultivate satisfaction and fulfillment. In today’s practice of…
IACH News of the Week IACH News of the Week, curated by Dr Edwin Uriel Suárez , is a weekly summary of the latest advancements…
We welcome you to join a special webinar for Practicing Hematologists on how to prevent burnout and cultivate satisfaction and fulfillment. In today’s practice of…
By Shakthi T Bhaskar, Bhagirathbhai Dholaria & 2 more. The Evolving Role of Bridging Therapy during CAR-T Therapy
